AKF webinar: Cystatin C and its utility as an alternative to creatinine

Cystatin C as a valuable marker for eGFR

Since its discovery in 1979¹, cystatin C has been widely recognised as a reliable marker for estimating glomerular filtration rate (GFR). GFR calculations performed using cystatin C are independent of factors such as protein intake, muscle mass and race^2-5. This means that cystatin C testing can help ensure an unbiased assessment of renal function, which is central to the diagnosis and management of chronic kidney disease (CKD). Clinical use of the biomarker marker has been recommended in guidelines published by Kidney Disease: improving Global outcomes (KDIGO)⁵ and Britain’s National Institute for Health and Care Excellence (NICE)⁶.

Working with the American Kidney Fund 

Gentian has joined forces with The American Kidney Fund (AKF), a leading US non-profit organisation with a steadfast commitment to fighting kidney disease on all fronts. Over the last 50 years, AKF has produced award-winning public and professional health education materials that have disseminated information vital to the global fight against kidney disease.

Webinar: Cystatin C and its utility as an alternative to creatinine

Gentian is also the proud sponsor of the AKF led webinar Cystatin C: Its utility as an alternative for creatinine-based eGFR on May 4^th 2021, 01:00 PM in US Eastern Time. The growing scrutiny over inclusion of race modifiers in creatinine-based eGFR equations has pushed measurement of cystatin C into the forefront of biomarkers that could help ensure better patient outcomes.

A multidisciplinary panel of experts will delve into the utility of the cystatin C test in diagnosing and managing kidney disease by discussing:

• Epidemiological argument for measuring cystatin C
• Benefits of cystatin C in eliminating racial bias & improving precision
• Case examples that speak to the clinical utility of cystatin C
• Practical barriers to the broader adoption of cystatin C

The moderator is Silas Norman, MD, MPH University of Michigan. Among the panellists we find Josef Coresh, MD, PhD, from Johns Hopkins University, Michelle Estrella, MD, MHS and Michael Shlipak, MD, MPH from University of California - San Francisco, Amy Karger, MD, PhD from University of Minnesota.

Why the Gentian Cystatin C Immunoassay

• In vitro diagnostic test for quantitative determination of cystatin C in human serum and plasma
• Particle-Enhanced Turbidimetric Immunoassay (PETIA)
• FDA510(k) cleared and CE-marked
• ERM-DA471/IFCC standardised
• Avian antibodies
• Available for a wide range of clinical analysers with documented high inter-instrument accuracy

Contact Gentian

Do you want to know more about cystatin C, our assay or how to implement cystatin C in your laboratory? Please fill out the form below or send an email to marketing@gentian.com.

References:

1. Löfberg H and AO Grubb. Quantitation of gamma-trace in human biological fluids: indications for production in the central nervous system, in Scand J Clin Lab Invest, 1979.

2. Mussap M, Plebani M. Biochemistry and clinical role of human cystatin C. Crit Rev Clin Lab Sci. 2004.

3. Grubb A. Cystatin C is Indispensable for Evaluation of Kidney Disease. EJIFCC. 2017;28(4):268-276. Published 2017 Dec 19.

4. Dale R Wagner, Vivian H Heyward. Measures of body composition in blacks and whites: a comparative review. The American Journal of Clinical Nutrition, Volume 71, Issue 6, June 2000.

5. KDIGO Guidelines 2012 published in Kidney International Supplements Vol3 Issue 1, Jan 2013.
6. NCIC Clinical guideline (CG182) updated jan 2015 section 2.1 https://www.nice.org.uk/guidance/cg182/chapter/2-Implementation-getting-started.